BioAtla, Inc. (NasdaqCM: BCAB)
Health Care · Biotechnology · US
$3.26
+2.52% today · -82.1% 1Y
BioAtla, Inc. (NasdaqCM: BCAB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $5.30M and employs 41 people.
Over the last twelve months the share price has lost 82.1%, trading between 2.81 and 71.50.
Tweenvest scores BioAtla, Inc. across four factors: quality 4/100, value 54/100. Its strongest factor is value.
BCAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.30M
- Revenue (TTM)
- $8.50M
- P/E
- —
- EPS
- -22.74
- Dividend yield
- —
- Beta (5Y)
- 0.76
- 52-week high
- $71.50
- 52-week low
- $2.81
- Avg volume (3M)
- —
- Shares outstanding
- 1.67M
- Employees
- 41
- Next earnings
- —
About BioAtla, Inc.
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
- ISIN
- US09077B2034
- Founded
- 2007
- Listed since
- Dec 16, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.96 | +0.06% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €894.20 | +1.71% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $158.83 | +14.36% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.